The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury.

MLA

Dutzmann, Jochen, et al. “The Novel Mineralocorticoid Receptor Antagonist Finerenone Attenuates Neointima Formation after Vascular Injury.” PloS One, vol. 12, no. 9, Sept. 2017, p. e0184888. EBSCOhost, https://doi.org/10.1371/journal.pone.0184888.

APA

Dutzmann, J., Musmann, R.-J., Haertlé, M., Daniel, J.-M., Sonnenschein, K., Schäfer, A., Kolkhof, P., Bauersachs, J., & Sedding, D. G. (2017). The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. PloS One, 12(9), e0184888. https://doi.org/10.1371/journal.pone.0184888

Chicago

Dutzmann, Jochen, Robert-Jonathan Musmann, Marco Haertlé, Jan-Marcus Daniel, Kristina Sonnenschein, Andreas Schäfer, Peter Kolkhof, Johann Bauersachs, and Daniel G Sedding. 2017. “The Novel Mineralocorticoid Receptor Antagonist Finerenone Attenuates Neointima Formation after Vascular Injury.” PloS One 12 (9): e0184888. doi:10.1371/journal.pone.0184888.